| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MSLP Stock Overview
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally.
MusclePharm Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$2.17 |
| 52 Week Low | US$0.12 |
| Beta | 0.20 |
| 1 Month Change | 0% |
| 3 Month Change | -37.93% |
| 1 Year Change | -91.71% |
| 3 Year Change | -48.28% |
| 5 Year Change | -90.00% |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| MSLP | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -5.8% | -4.5% | -2.5% |
| 1Y | -91.7% | -24.0% | -21.2% |
Return vs Industry: MSLP underperformed the US Personal Products industry which returned -24.7% over the past year.
Return vs Market: MSLP underperformed the US Market which returned -21.7% over the past year.
Price Volatility
| MSLP volatility | |
|---|---|
| MSLP Average Weekly Movement | 31.9% |
| Personal Products Industry Average Movement | 11.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MSLP is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.
Volatility Over Time: MSLP's weekly volatility has increased from 23% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 21 | Ryan Drexler | https://www.musclepharm.com |
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products.
MusclePharm Fundamentals Summary
| MSLP fundamental statistics | |
|---|---|
| Market Cap | US$6.03m |
| Earnings (TTM) | -US$19.26m |
| Revenue (TTM) | US$50.02m |
0.1x
P/S Ratio-0.3x
P/E RatioIs MSLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSLP income statement (TTM) | |
|---|---|
| Revenue | US$50.02m |
| Cost of Revenue | US$46.83m |
| Gross Profit | US$3.19m |
| Other Expenses | US$22.45m |
| Earnings | -US$19.26m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 6.38% |
| Net Profit Margin | -38.51% |
| Debt/Equity Ratio | -58.9% |
How did MSLP perform over the long term?
See historical performance and comparisonValuation
Is MSLP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MSLP?
Other financial metrics that can be useful for relative valuation.
| What is MSLP's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$6.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -2.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MSLP's PS Ratio compare to its peers?
| MSLP PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
CVSI CV Sciences | 0.3x | 13.3% | US$5.2m |
GLUC Glucose Health | 8x | n/a | US$7.5m |
SLGD Scott's Liquid Gold-Inc | 0.3x | n/a | US$8.8m |
EWLU Merion | 4x | n/a | US$4.8m |
MSLP MusclePharm | 0.1x | n/a | US$6.0m |
Price-To-Sales vs Peers: MSLP is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.2x).
Price to Earnings Ratio vs Industry
How does MSLP's PE Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Sales vs Industry: MSLP is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Personal Products industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is MSLP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MSLP's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MSLP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MSLP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MSLP's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSLP's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at our analysis of MSLP's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through MusclePharm regulatory filings here.
Future Growth
How is MusclePharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
12.7%
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MusclePharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of MSLP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MusclePharm's filings and announcements here.
Past Performance
How has MusclePharm performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-6.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSLP is currently unprofitable.
Growing Profit Margin: MSLP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSLP is unprofitable, and losses have increased over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare MSLP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSLP is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (37.3%).
Return on Equity
High ROE: MSLP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is MusclePharm's financial position?
Financial Health Score
2/6Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MSLP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MSLP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MSLP has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MSLP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSLP has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: MSLP is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Dividend
What is MusclePharm current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSLP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSLP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSLP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSLP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MSLP has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Ryan Drexler (51 yo)
6.25yrs
Tenure
US$1,639,817
Compensation
Mr. Ryan Charles Drexler serves as the Chief Executive Officer of Consac, LLC. Mr. Drexler serves as Chief Executive Officer at MusclePharm Corporation and served as its President. He has been Executive Ch...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD1.64M) is above average for companies of similar size in the US market ($USD765.69K).
Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: MSLP's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Experienced Board: MSLP's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MusclePharm Corporation's employee growth, exchange listings and data sources
Key Information
- Name: MusclePharm Corporation
- Ticker: MSLP
- Exchange: OTCPK
- Founded: 2006
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: US$6.026m
- Shares outstanding: 33.48m
- Website: https://www.musclepharm.com
Number of Employees
Location
- MusclePharm Corporation
- 6728 West Sunset Road
- Suite 130
- Las Vegas
- Nevada
- 89119
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/01 00:00 |
| End of Day Share Price | 2022/07/01 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.